Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 17, 2009

Synta Obtains $10M from GSK under Cancer Deal

  • Synta Pharmaceuticals achieved an operational milestone triggering a $10 million payment from GlaxoSmithKline (GSK) under its collaboration for elesclomol. The drug is currently being studied in combination with paclitaxel in a Phase III trial in metastatic melanoma.

    In October 2007, Synta and GSK inked a deal covering elesclomol that was worth $965 million. Synta has earned a total of $130 million to date, including $80 million up front and $25 million for milestones achieved in October and  $15 million for milestones achieved in December 2008.

    The company is eligible for a total of $585 million in precommercial milestone payments: $150 related to development in melanoma and the remainder related to other cancer indications.  Synta is also eligible to $300 million in sales milestones, 40-50% share of operating profits in the U.S., and double-digit royalties on ex-U.S. sales.

    Elesclomol is an investigational first-in-class oxidative stress inducer that triggers apoptosis in cancer cells. Enrollment for the Phase III study was completed earlier this month.

     

    ---

    To comment on this story, go to BLOGbiotech.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »